Sugi Predict

Sugi Predict / Targets / SKP1

SKP1

S-phase kinase-associated protein 1 (Cyclin-A · P63208 · SKP1 on Sugi Atlas →

23,368 patent compounds predicted against SKP1, 9,991 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Selexipag Selexipag (SCHEMBL674122) 1.00 8/20
SCHEMBL618489 SCHEMBL618489 0.50 8/20
Selexipag Selexipag (SCHEMBL1258587) 0.82 7/20
Laselipag Laselipag (SCHEMBL1259149) 0.61 7/20
Laselipag Laselipag (SCHEMBL1259176) 0.61 7/20
Laselipag Laselipag (SCHEMBL676234) 0.77 6/20
SCHEMBL383762 SCHEMBL383762 0.53 5/20
SCHEMBL973782 SCHEMBL973782 0.45 5/20
SCHEMBL616986 SCHEMBL616986 0.49 4/20
SCHEMBL617002 SCHEMBL617002 0.49 4/20
SCHEMBL615185 SCHEMBL615185 0.42 4/20
SCHEMBL617577 SCHEMBL617577 0.66 3/20
SCHEMBL530038 SCHEMBL530038 0.61 3/20
SCHEMBL617173 SCHEMBL617173 0.54 3/20
SCHEMBL617174 SCHEMBL617174 0.54 3/20
SCHEMBL614945 SCHEMBL614945 0.51 3/20
SCHEMBL476267 SCHEMBL476267 0.46 3/20
SCHEMBL617904 SCHEMBL617904 0.44 3/20
SCHEMBL617515 SCHEMBL617515 0.42 3/20
SCHEMBL1480048 SCHEMBL1480048 0.63 2/20

Clinical trials — most relevant to SKP1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Effect of Silymarin in Metastatic Colorectal Cancer Patients PHASE3UNKNOWN
A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer PHASE3COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer PHASE2COMPLETED
Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC PHASE2COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors PHASE2RECRUITING
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck PHASE2COMPLETED
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma PHASE2RECRUITING
Study of MLN8237 in Combination With Irinotecan and Temozolomide PHASE1/PHASE2COMPLETED
9-ING-41 in Patients With Advanced Cancers PHASE2ACTIVE_NOT_RECRUITING
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors PHASE1COMPLETED
Phase 1 Study of MKC-1 in Patients With Advanced Cancer PHASE1COMPLETED
Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma PHASE1WITHDRAWN
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 PHASE1RECRUITING
Study of ABT-751 in Patients With Refractory Hematologic Malignancies PHASE1COMPLETED
SNX-5422 to Treat Solid Tumor Cancers and Lymphomas PHASE1COMPLETED
Vulvodynia: Identification of Potential Relevant Biomarkers nanCOMPLETED
Study of Proteins in Head and Neck Cancer Cells nanCOMPLETED
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies nanENROLLING_BY_INVITATION
PCM1-JAK2 in Therapy Related Neoplasms nanUNKNOWN
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period nanUNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SKP1 binder may also engage these)

ProteinNameSimilarity
P63209 — 1.000 P63209 →
Q4R5B9 — 1.000 Q4R5B9 →
Q9WTX5 — 1.000 Q9WTX5 →
Q5ZKF5 — 1.000 Q5ZKF5 →
Q5R512 — 1.000 Q5R512 →
Q3ZCF3 — 0.999 Q3ZCF3 →
Q6PEC4 — 0.999 Q6PEC4 →
Q71U00 — 0.998 Q71U00 →
B0Y3B5 — 0.991 B0Y3B5 →
A1CZG3 — 0.991 A1CZG3 →
Q5KU00 — 0.991 Q5KU00 →
Q0CA59 — 0.990 Q0CA59 →
A1C9U5 — 0.990 A1C9U5 →
D4ARL8 — 0.989 D4ARL8 →
B6QGB9 — 0.989 B6QGB9 →
Q8TGW7 — 0.987 Q8TGW7 →
Q4WTT8 — 0.986 Q4WTT8 →
B8NSJ0 — 0.984 B8NSJ0 →
C5FHU9 — 0.981 C5FHU9 →
Q5BAX8 — 0.980 Q5BAX8 →
Q6PL11 — 0.979 Q6PL11 →
G5ECU1 — 0.978 G5ECU1 →
Q9LNT9 — 0.976 Q9LNT9 →
Q8NK13 — 0.976 Q8NK13 →
B8MDP8 — 0.975 B8MDP8 →
P52285 — 0.974 P52285 →
Q9Y709 — 0.973 Q9Y709 →
Q9FHW7 — 0.972 Q9FHW7 →
Q557E4 — 0.972 Q557E4 →
Q39255 — 0.968 Q39255 →